Protagenic Therapeutics IncNASDAQ:PTIX
- LAST PRICE1.9900
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.8000/ 2
- Ask / Lots2.4000/ 1
- Open / Previous Close2.0329 / 1.9900
- Day Range
- 52 Week Range
- Volume1,890
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | PTIX |
|---|---|---|
| 01:51 ET | 401 | 2.0329 |
| 03:07 ET | 100 | 2.07 |
| 03:48 ET | 597 | 2.0423 |
| 03:57 ET | 200 | 1.99 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Protagenic Therapeutics Inc | 8.8M | -3.0x | --- |
Avenue Therapeutics Inc | 8.8M | -0.5x | --- |
Check Cap Ltd | 8.7M | 0.0x | --- |
Palisade Bio Inc | 8.9M | -0.1x | --- |
Connect Biopharma Holdings Ltd | 61.1M | 0.0x | --- |
Innovation Pharmaceuticals Inc | 8.9M | -2.3x | --- |
Company Information
Protagenic Therapeutics, Inc. is a biopharmaceutical company. The Company specializes in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide (TCAP), an endogenous brain signaling peptide that can dampen overactive stress responses. Its lead compound is a 41-residue peptide synthetic TCAP-1. In addition, it has a portfolio of earlier stage neuropeptides targeting the TCAP pathway that are in preclinical evaluation. PT00114 has also demonstrated pre-clinical efficacy in a murine model of opioid withdrawal called the Saleens test. Its preclinical models have demonstrated the efficacy of PT00114 in animal models of depression, anxiety, substance abuse and addiction, and PTSD.
Contact Information
- Headquarters
- 149 FIFTH AVENUE, SUITE 500NEW YORK, NY, United States 10010
- Phone
- 212-994-8200
- Fax
- 302-636-5454
Executives
- Executive Chairman of the Board
- Garo Armen
- Chief Financial Officer
- Alexander Arrow
- Chief Operating Officer
- Andrew Slee
- Director, Chief Medical Officer
- Robert Stein
- Director
- Timothy Wright
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $8.8M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 4.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.71 |
EPS | $-0.67 |
Book Value | $1.60 |
P/E Ratio | -3.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
